ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1489

Incidence of Herpes Zoster Events After the Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis
Abstract Number: 0861

Incidence of Juvenile Idiopathic Arthritis During the COVID-19 Pandemic: An Analysis of National United States Administrative Claims Data
Abstract Number: 1081

Incidence of Pneumocystis Jiroveci Pneumonia in Patients with ANCA Vasculitis Initiating Therapy with Rituximab or Cyclophosphamide
Abstract Number: 1594

Incidence of Pneumocystis Jirovecii Pneumonia and Prophylaxis-Associated Adverse Events Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1244

Incidence of Radiographic Spinal Damage in Psoriatic Arthritis Patients Compared to Spondyloarthritis Patients: Which Patients Are More Affected?
Abstract Number: 0450

Incidence of Solid and Hematologic Tumors in Patients with ANCA: A 10-year Retrospective Cohort Study
Abstract Number: 0388

Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States
Abstract Number: 0872

Incidence, Risk Factors, and Outcomes of Eosinophilia on IL-1 and IL-6 Inhibitors in Systemic and Non-Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0944

Inconsistent Family Planning Documentation in Women with Interstitial Pneumonia with Autoimmune Features (IPAF)
Abstract Number: 0587

Increase of Intercellular Adhesion Molecule-1 Linked to Lung Damage of Interstitial Lung Disease in Patients with Autoimmune Diseases
Abstract Number: 0123

Increase of Serum Endothelin-1 Levels in Patients with Interstitial Lung Disease Associated with Autoimmune Diseases
Abstract Number: 0535

Increase Rates of Bacterial Infection in Patients with ‘Pre-RA’
Abstract Number: 2256

Increased Brain Functional Connectivity to the Insula Is Associated with Nociplastic Pain in Psoriatic Arthritis
Abstract Number: 1746

Increased CD39+FoxP3+CD4+ Regulatory T Cells in Early Rheumatoid Arthritis Provide a Slot for Prompt Initiation of Methotrexate and Serve as Early Biomarkers of Clinical Response
Abstract Number: 0797

Increased Duration of Mycophenolate Hold Improves Antibody Response to SARS-CoV-2 Vaccination in Patients with Rheumatic and Musculoskeletal Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].